EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
NCT ID: NCT02240784
Last Updated: 2021-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
136 participants
OBSERVATIONAL
2014-08-31
2021-04-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
NCT03547297
Prevalence of Acute Hepatic Porphyria
NCT04923516
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
NCT03056612
Integrative Epidemiology of Prognosis in Patients With Acute Alcoholic Hepatitis at AP-HP
NCT07262515
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute Hepatic Porphyria
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of AHP \[acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP) and aminolevulinic acid dehydratase (ALAD) deficient porphyria (ADP)\]
* Porphyria attacks in the past 12 months or receiving treatment to prevent attacks
* Willing to provide written informed consent, medical records, and to comply with study requirements
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Alnylam Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Miami, Florida, United States
Clinical Trial Site
Ann Arbor, Michigan, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Winston-Salem, North Carolina, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Galveston, Texas, United States
Clinical Trial Site
Salt Lake City, Utah, United States
Clinical Trial Site
Camperdown, New South Wales, Australia
Clinical Trial Site
Leuven, , Belgium
Clinical Trial Site
Sofia, , Bulgaria
Clinical Trial Site
Prague, , Czechia
Clinical Trial Site
Helsinki, , Finland
Clinical Trial Site
Paris, , France
Clinical Trial Site
Chemnitz, , Germany
Clinical Trial Site
Petah Tikva, , Israel
Clinical Trial Site
Milan, , Italy
Clinical Trial Site
Modena, , Italy
Clinical Trial Site
Mexico City, , Mexico
Clinical Trial Site
Rotterdam, , Netherlands
Clinical Trial Site
Bergen, , Norway
Clinical Trial Site
Warsaw, , Poland
Clinical Trial Site
Cape Town, , South Africa
Clinical Trial Site
Seoul, , South Korea
Clinical Trial Site
Barcelona, , Spain
Clinical Trial Site
Murcia, , Spain
Clinical Trial Site
Zurich, , Switzerland
Clinical Trial Site
Taipei, , Taiwan
Clinical Trial Site
Cardiff, Wales, United Kingdom
Clinical Trial Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-AS1-NT-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.